KOPRAN Latest Share Price (KOPRAN)
TODAY IN ONE LINE
KOPRAN is little changed at ₹232.54 on above-average volume (4330039.3x avg) — a quiet consolidation day.
With a market cap of ₹1,120.23 Cr., it trades at a P/E of 37.34. Track live valuations, technical indicators, and peers comparison below. Check delivery conviction and recent filings to build your view.
How good is this company?
Overall performance across 5 key dimensions.
KOPRAN flags & news
Key strengths, potential risks, and recent updates.
Green Flags
- ●Strong Price MomentumRobust returns of 68.6% over 1Y
- ●Steady Dividend YieldReliable 2.76% dividend yield
- ●Virtually Debt-FreeVery low Debt-to-Equity of 0.29x
- ●Zero Pledge RiskNo recent active promoter pledging found
Red Flags
- ●Earnings DeclineEPS (TTM) has contracted by 71.9% YoY
- ●Sales ContractionQuarterly sales dropped 59.3% YoY
- ●Poor Capital ReturnsLow ROE of 4.8%
- ●Rising Receivables vs SalesReceivables grew 18.4% outpacing sales growth of 2.4%
Latest KOPRAN News
What changed recently?
Recent events, corporate actions, and announcements.
KOPRAN valuation: P/E, P/B and sector benchmarks.
Twelve years of multiples investors have paid for KOPRAN, framed against the sector median so the premium or discount is obvious at a glance.
KOPRAN trades at a P/E of 37.34× and P/B of 1.76×.
Market-priced ratios use the latest available quote; accounting metrics use the latest reported filing. Compare values with matched peers and the company's own history.
Valuation
Profitability
Growth
Financial Health
KOPRAN technical analysis: indicators, pivots and CPR.
Latest RSI, MACD and moving-average signals plus the latest pivot and Central Pivot Range levels for KOPRAN — derived from the latest tape, not yesterday's close.
KOPRAN last traded at ₹232.54 with an intraday range of ₹229.29–₹242.8 — latest indicator, pivot and CPR signals below.
Pivot points
Standard pivot — most widely referenced.
Pivot levels · Classic
Last: ₹232.54| Level | Price (₹) | Distance | % Δ |
|---|---|---|---|
| R4 | 267.48 | +34.94 | +15.03% |
| R3 | 253.97 | +21.43 | +9.22% |
| R2 | 248.39 | +15.85 | +6.81% |
| R1 | 240.46 | +7.92 | +3.41% |
| PIVOT | 234.88 | 2.34 | 1.00% |
| CURRENT | 232.54 | — | — |
| S1 | 226.95 | -5.59 | -2.40% |
| S2 | 221.37 | -11.17 | -4.80% |
| S3 | 213.44 | -19.10 | -8.21% |
| S4 | 199.93 | -32.61 | -14.02% |
KOPRAN is trading Below CPR, indicating Bearishness
CPR is Wider, suggesting unlikely for trending moves
Day's range: ₹229.29–₹242.8
Trading Inside opening range
KOPRAN financials: P&L, balance sheet, cash flow, ratios.
Reported annual and quarterly results for KOPRAN — consolidated or standalone — with margins, YoY growth and key ratios inline.
KOPRAN reports its full P&L, balance sheet, cash flow and ratios on this page — current market capitalisation of ₹1,120.23 Cr. and reported EPS of ₹1.39.
| Metric | Mar 2025 | Mar 2026 |
|---|---|---|
| Revenue from Operations | 630 | 681 ▲ 8.2% |
| Sales Growth YoY %Derived | 2.44% | 8.23% |
| Other Income | 4 | 0 ▼ 91.3% |
| Total Income | 634 | 682 ▲ 7.6% |
| 405 | 439 ▲ 8.5% | |
| Gross ProfitDerived | 225 | 242 ▲ 7.7% |
| Gross Margin %Derived | 35.73% | 35.57% |
| 152 | 180 ▲ 18.7% | |
| EBITDA (Operating Profit)Derived | 73 | 62 ▼ 15.0% |
| OPM %Derived | 11.58% | 9.09% |
| 25 | 28 ▲ 12.1% | |
| Profit Before Tax (PBT) | 52 | 34 ▼ 33.9% |
| 13 | 9 ▼ 35.6% | |
| Effective Tax %Derived | 25.79% | 25.10% |
| Total Profit for Period | 39 | 26 ▼ 33.3% |
| Net Profit (Owner's PAT)Derived | 39 | 26 ▼ 33.3% |
| Net Profit Margin %Derived | 6.12% | 3.78% |
| PAT Growth YoY %Derived | -24.34% | -33.26% |
| Earnings Per Share (EPS ₹) | 7.98 | 5.33 ▼ 33.2% |
| Diluted Shares Outstanding (Cr) | 5 | 5 ▲ 0.0% |
| Other Comprehensive Income (Net of Tax) | -1 | 1 ▲ 165.2% |
| Total Expenses (incl. D&A & Interest) | 582 | 647 ▲ 11.3% |
| Material Cost % of RevenueDerived | 63.69% | 63.28% |
| Employee Cost % of RevenueDerived | 9.61% | 9.57% |
| Other Cost % of RevenueDerived | 14.54% | 16.91% |
| Interest Coverage (x)Derived | 6.14x | 4.25x |
| Period | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | Trend |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue from Operations | 315 | 358 ▲ 13.7% | 359 ▲ 0.4% | 492 ▲ 36.8% | 478 ▼ 2.9% | 551 ▲ 15.4% | 615 ▲ 11.5% | 630 ▲ 2.4% | 681 ▲ 8.2% | |
| Sales Growth YoY %Derived | — | 13.72% | 0.45% | 36.81% | -2.91% | 15.38% | 11.54% | 2.44% | 8.23% | |
| Other Income | 10 | 3 ▼ 68.1% | 1 ▼ 79.4% | 18 ▲ 2751.9% | 11 ▼ 41.0% | 3 ▼ 71.1% | 15 ▲ 376.7% | 4 ▼ 72.7% | 0 ▼ 91.3% | |
| Total Income | 324 | 361 ▲ 11.3% | 360 ▼ 0.2% | 510 ▲ 41.6% | 488 ▼ 4.3% | 554 ▲ 13.5% | 629 ▲ 13.6% | 634 ▲ 0.7% | 682 ▲ 7.6% | |
188 | 208 ▲ 10.6% | 210 ▲ 1.0% | 302 ▲ 43.7% | 271 ▼ 10.1% | 359 ▲ 32.1% | 402 ▲ 12.1% | 405 ▲ 0.7% | 439 ▲ 8.5% | ||
| Gross ProfitDerived | 127 | 150 ▲ 18.4% | 149 ▼ 0.3% | 190 ▲ 27.1% | 206 ▲ 8.5% | 192 ▼ 6.7% | 213 ▲ 10.5% | 225 ▲ 5.8% | 242 ▲ 7.7% | |
| Gross Margin %Derived | 40.24% | 41.89% | 41.58% | 38.64% | 43.17% | 34.92% | 34.60% | 35.73% | 35.57% | |
96 | 104 ▲ 7.6% | 103 ▼ 0.8% | 108 ▲ 5.3% | 119 ▲ 9.7% | 141 ▲ 18.4% | 138 ▼ 1.7% | 152 ▲ 10.0% | 180 ▲ 18.7% | ||
| EBITDA (Operating Profit)Derived | 30 | 46 ▲ 52.4% | 47 ▲ 0.8% | 82 ▲ 75.1% | 87 ▲ 6.9% | 52 ▼ 40.7% | 74 ▲ 43.7% | 73 ▼ 2.0% | 62 ▼ 15.0% | |
| OPM %Derived | 9.66% | 12.95% | 12.99% | 16.63% | 18.30% | 9.40% | 12.11% | 11.58% | 9.09% | |
17 | 18 ▲ 3.6% | 18 ▲ 1.2% | 16 ▼ 8.4% | 16 ▼ 1.3% | 19 ▲ 15.9% | 21 ▲ 14.3% | 25 ▲ 16.1% | 28 ▲ 12.1% | ||
| Profit Before Tax (PBT) | 23 | 32 ▲ 38.4% | 28 ▼ 10.7% | 83 ▲ 194.6% | 82 ▼ 1.9% | 36 ▼ 55.9% | 68 ▲ 87.3% | 52 ▼ 23.1% | 34 ▼ 33.9% | |
2 | 8 ▲ 218.4% | 7 ▼ 4.9% | 22 ▲ 199.2% | 21 ▼ 4.5% | 9 ▼ 57.4% | 17 ▲ 87.8% | 13 ▼ 19.2% | 9 ▼ 35.6% | ||
| Effective Tax %Derived | 10.48% | 24.13% | 25.68% | 26.07% | 25.37% | 24.49% | 24.56% | 25.79% | 25.10% | |
| Total Profit for Period | 20 | 24 ▲ 17.3% | 21 ▼ 12.5% | 62 ▲ 193.1% | 61 ▼ 0.9% | 27 ▼ 55.4% | 51 ▲ 87.1% | 39 ▼ 24.3% | 26 ▼ 33.3% | |
| Net Profit (Owner's PAT)Derived | 20 | 24 ▲ 17.3% | 21 ▼ 12.5% | 62 ▲ 193.1% | 61 ▼ 0.9% | 27 ▼ 55.4% | 51 ▲ 87.1% | 39 ▼ 24.3% | 26 ▼ 33.3% | |
| Net Profit Margin %Derived | 6.51% | 6.71% | 5.85% | 12.53% | 12.78% | 4.94% | 8.29% | 6.12% | 3.78% | |
| PAT Growth YoY %Derived | — | 17.26% | -12.50% | 193.08% | -0.93% | -55.38% | 87.11% | -24.34% | -33.26% | |
| Earnings Per Share (EPS ₹) | 4.74 | 5.55 ▲ 17.1% | 4.86 ▼ 12.4% | 14.24 ▲ 193.0% | 12.66 ▼ 11.1% | 5.65 ▼ 55.4% | 10.57 ▲ 87.1% | 7.98 ▼ 24.5% | 5.33 ▼ 33.2% | |
| Diluted Shares Outstanding (Cr) | 4 | 4 ▲ 0.0% | 4 ▲ 0.0% | 4 ▼ 0.0% | 5 ▲ 11.5% | 5 ▲ 0.0% | 5 ▲ 0.0% | 5 ▲ 0.2% | 5 ▲ 0.0% | |
| Other Comprehensive Income (Net of Tax) | 0 | -0 ▼ 523.7% | 0 ▲ 172.1% | 0 ▲ 23.5% | 0 ▼ 47.5% | 0 ▲ 156.8% | 0 ▼ 32.9% | -1 ▼ 485.7% | 1 ▲ 165.2% | |
| Total Expenses (incl. D&A & Interest) | 301 | 329 ▲ 9.2% | 332 ▲ 0.8% | 426 ▲ 28.5% | 406 ▼ 4.7% | 518 ▲ 27.5% | 562 ▲ 8.4% | 582 ▲ 3.6% | 647 ▲ 11.3% | |
| Material Cost % of RevenueDerived | 55.98% | 54.82% | 62.05% | 53.97% | 62.27% | 58.37% | 64.25% | 63.69% | 63.28% | |
| Employee Cost % of RevenueDerived | 10.24% | 10.37% | 10.25% | 7.56% | 9.06% | 9.06% | 8.51% | 9.61% | 9.57% | |
| Other Cost % of RevenueDerived | 20.34% | 18.58% | 18.34% | 14.45% | 15.81% | 16.46% | 13.99% | 14.54% | 16.91% | |
| Interest Coverage (x)Derived | 2.55x | 4.18x | 4.17x | 11.47x | 14.91x | 6.42x | 7.16x | 6.14x | 4.25x |
KOPRAN segment analysis : revenue and profit mix.
Disclosed business segments at KOPRAN with their share of revenue and profit, switchable between consolidated and standalone reporting.
KOPRAN discloses revenue and profit across multiple business segments — toggle between consolidated and standalone views to see the mix.
Segment-wise Financial Analysis
The Bull, Bear, and Flip case for KOPRAN.
Our AI distills the core fundamental drivers supporting KOPRAN, the risks that threaten it, and the quantitative conditions that could weaken the thesis.
KOPRAN's investment case rests on 10 positive markers and 10 flagged concerns drawn from the latest reported filings.
What you're getting.
Minimal debt burden with debt-to-equity ratio of 0.0029, providing exceptional financial flexibility.
Operating margin of 6.58% demonstrates reasonable cost control amid pharmaceutical manufacturing challenges.
Price-to-book ratio of 0.98 suggests stock trading near tangible asset value, offering potential value.
Diversified pharmaceutical portfolio spanning APIs, tablets, capsules, injectables across multiple therapeutic areas.
Long operational history since 1958 with established distribution networks in domestic and international markets.
Key Risks.
Latest quarterly EPS declined 10.23% YoY despite revenue growth, signaling profitability pressure.
TTM EPS declined 71.88% YoY, indicating severe recent earnings deterioration requiring urgent investigation.
Quarterly sales declined 59.25%, reflecting sharp demand contraction or significant operational disruptions.
Return on equity of 4.85% and ROCE of 4.89% significantly below pharmaceutical sector benchmarks.
High payout ratio of 87.90% limits reinvestment capacity for growth and R&D initiatives.
Flip Conditions.
Valuation risk. a P/E above 49 would leave less room for earnings disappointment.
Reassess if quarterly profit growth turns negative for two consecutive quarters. The bull case relies on compounding earnings.
Watch interest coverage if debt-to-equity climbs above 1.00. Balance sheet risk re-prices growth multiples fast.
Return-quality risk. ROE below 8% would indicate weaker capital compounding.
KOPRAN peer comparison — same-sector benchmarks.
Same-sector listed peers ranked on P/E, market cap, dividend yield and growth — KOPRAN is highlighted for quick read-across.
Quick Compare
Peer Comparison
| Company Name |
|---|
KOPRAN chart patterns: breakouts, tops and bottoms.
Auto-detected classical chart patterns for KOPRAN — Double Top/Bottom, Head & Shoulders, Triple Bottom and more — with break levels, targets and quality scores across Intraday, Daily and Weekly timeframes.
KOPRAN delivery volume — last 20 sessions of conviction.
Daily traded volume and delivery percentage for KOPRAN over 20 sessions — the gap between intraday flipping and genuine accumulation.
Latest session delivery in KOPRAN stood at 48.6% of traded volume, against a 20-day average of 38.2%.
KOPRAN announcements: results, concalls, ratings, M&A.
Filings KOPRAN sent to the exchanges, sequenced as they hit the tape — concall transcripts, results, credit ratings and presentations.
KOPRAN files concall transcripts, results, credit ratings and corporate-action notices on the NSE and BSE exchange portals — latest 61 documents below.
Spurt in Volume
Significant increase in volume has been observed in Kopran Limited. The Exchange, in order to ensure that investors have latest relevant information…
Spurt in Volume
Significant increase in volume has been observed in Kopran Limited. The Exchange, in order to ensure that investors have latest relevant information…
Shareholders meeting
Proceedings of AGM, Voting result and Scrutiniser's report.
Copy of Newspaper Publication
Kopran Limited has informed the Exchange about Copy of Newspaper Publication
Investor Presentation
Kopran Limited has informed the Exchange about Investor Presentation
Investor decks & rating reports.
Investor Presentation
Investor Presentation
Investor Presentation
Investor Presentation
Outcome of Board Meeting
KOPRAN dividend history, splits and bonus issues.
Every dividend, stock split and bonus issue KOPRAN has declared, sequenced by announce and record date.
KOPRAN corporate-action history below covers all declared dividends, stock splits and bonus issues recorded with NSE and BSE.
KOPRAN insider trading: promoter and management activity.
Promoter, director and designated-employee transactions in KOPRAN as reported to SEBI — buying and selling signals from the people who know the business best.
KOPRAN insider activity below tracks 2 reported promoter, director and designated-employee transactions under SEBI Regulation 7(2).
| Insider | Category | Txn Date | Action | Quantity | Value (₹) | Price |
|---|---|---|---|---|---|---|
| Mridula Somani | Insider | 18 Dec 2024 | buy | +17.65 L | — | — |
| Mridula Somani | Insider | 18 Dec 2024 | buy | +17.65 L | — | — |
About KOPRAN: business, sector, key facts.
What KOPRAN does, where it operates, the people running it, and the numbers that describe the entity behind the ticker.
KOPRAN operates in the Pharmaceuticals industry under the Healthcare sector, listed as NSE: KOPRAN, BSE: 524280.
Kopran Limited is an integrated pharmaceutical company with a long history, established in 1958 and headquartered in Mumbai, India. Its core business revolves around the manufacturing and marketing of both Active Pharmaceutical Ingredients (APIs) and finished dosage forms of pharmaceuticals. This encompasses a broad range of products distributed both domestically within India and internationally.
The company's product portfolio is extensive and diverse, covering numerous therapeutic categories. Their finished dosage forms include a variety of common pharmaceutical presentations such as tablets, capsules, syrups, dry powders, suspensions, and injectables. These forms are utilized to deliver medications across a wide spectrum of therapeutic areas.
Kopran offers both branded and generic formulations of drugs. The therapeutic areas covered by their products are substantial, including but not limited to: macrolides, antibacterials, anticonvulsants, anti-hypertensives, anti-helminthics, anti-acne medications, anti-infectives, anti-thrombotics, antidiabetics, pain management medications, neuromodulators, gastroenterology drugs, and cardiovascular medications. Furthermore, their offerings extend to drugs for erectile dysfunction, antiallergics, respiratory medications, oncology drugs, central nervous system medications, antiprotozoals, anthelmintics, antipeptic ulcer and gut medications, and various other therapeutic categories.
In summary, Kopran Limited operates as a fully integrated pharmaceutical company, encompassing API production and the manufacturing and marketing of a wide range of finished dosage forms across numerous therapeutic areas. Their long history and diverse product portfolio establish them as a significant player in the Indian and international pharmaceutical markets.
Related
Peers, sector trends, screeners and strategy playbooks contextual to this stock.
- AAREY DRUGS & PHARM (AAREYDRUGS) Share PricePeer
- AARTI DRUGS (AARTIDRUGS) Share PricePeer
- AARTI PHARMALABS (AARTIPHARM) Share PricePeer
- AJANTA PHARMA (AJANTPHARM) Share PricePeer
- AKUMS DRUGS AND PHARMA L (AKUMS) Share PricePeer
- Stocks near 52-week high (breakout watch)Screener
- Breakout Trader strategy playbookStrategy
- Top Gainers TodayScreener
- EMA Crossover ScreenerScreener
- Stock Quality ScorecardScreener
- Technical DashboardScreener
- Results CalendarScreener
- FII Buying ActivityScreener
- All Technical ScreenersScreener
Questions investors ask about KOPRAN (KOPRAN).
Quick answers grounded in this page's data — price action, fundamentals, ratios and ownership.
01What is the current share price of KOPRAN (KOPRAN)?
The current share price of KOPRAN (KOPRAN) is ₹232.54. Today, the stock has gained by ₹0.30 (0.13%), trading in a range of ₹229.29 to ₹242.80. The stock opened at ₹232.40 with a trading volume of 6,61,197 shares.
02Is KOPRAN stock a good investment for long-term?
KOPRAN can be considered for long-term investment based on several factors. The company has a market capitalization of ₹1,120.23 Cr., P/E ratio of 37.34, ROE of 4.85%, and ROCE of 4.89%. The dividend yield stands at 2.76%. However, investment decisions should be based on your financial goals, risk appetite, and thorough research. It's recommended to consult with a SEBI-registered financial advisor before making investment decisions.
03What is the 52-week high and low price of KOPRAN stock?
The 52-week high price of KOPRAN (KOPRAN) is ₹239.60, while the 52-week low is ₹107.00. Currently trading at ₹232.54, the stock is 117.33% above its 52-week low and 2.95% below its 52-week high. These levels help investors understand the stock's price volatility and trading range over the past year.
04Should I buy KOPRAN stock at the current price?
Whether to buy KOPRAN stock at ₹232.54 depends on multiple factors. The stock is currently trading with a P/E ratio of 37.34 and P/B ratio of 1.76. Today's performance shows a gain of 0.13%. Consider analyzing the company's fundamentals, technical indicators, industry trends, and your investment horizon. Compare these metrics with industry peers and consult a financial advisor for personalized advice.
05What is the dividend yield of KOPRAN and when is the next dividend?
KOPRAN offers a dividend yield of 2.76%, which means for every ₹100 invested at the current price of ₹232.54, you can expect to receive approximately ₹2.76 annually as dividends. The face value of the stock is ₹10.00. For information about the next dividend announcement and ex-dividend date, please check the company's official announcements or visit the BSE/NSE websites.
06What are the key financial ratios and metrics of KOPRAN?
KOPRAN's key financial metrics include: P/E Ratio: 37.34, P/B Ratio: 1.76, ROE: 4.85%, ROCE: 4.89%, Dividend Yield: 2.76%, EPS: ₹1.39, Book Value: ₹109.82, and Debt-to-Equity: 0.29. The company's market cap stands at ₹1,120.23 Cr.. These metrics help evaluate the company's valuation, profitability, and financial health.
07How is KOPRAN stock performing today in the market?
KOPRAN stock opened at ₹232.40 and is currently trading at ₹232.54, showing a gain of ₹0.30 (0.13%). The intraday high is ₹242.80 and low is ₹229.29. The trading volume stands at 6,61,197 shares, indicating moderate market participation today.
08What is the P/E ratio of KOPRAN and what does it indicate?
KOPRAN has a Price-to-Earnings (P/E) ratio of 37.34, which means investors are willing to pay 37.34 for every ₹1 of earnings. With an EPS of ₹1.39, this P/E ratio suggests the stock may be trading at a premium, possibly due to high growth expectations. Compare this with industry peers and historical P/E ratios for better context.
The data, ratios and commentary about KOPRAN (KOPRAN) on this page are published for educational and informational purposes only and are not investment, legal or tax advice. StockeZee is not a SEBI-registered investment adviser, research analyst or portfolio manager, and no content here should be construed as a recommendation to buy, hold or sell any security. Live and historical market data may be delayed, revised by the exchanges, or contain errors; figures sourced from third-party feeds and corporate disclosures may not always be current. Past performance is not indicative of future results, and equity investments carry the risk of capital loss. Before acting on anything you read here, please consult a SEBI-registered financial advisor and read all scheme-related documents carefully.